NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Diagnostics & Research · USD

Biodesix, Inc. (BDSX) Stock Analysis

Biodesix, Inc. (BDSX) is a Diagnostics & Research stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

BDSX

$23.93

+$0.06 (+0.25%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare BDSX with… →

BDSX Key Statistics

As of Oct 21, 2026
Trading
Open
$24.12
Previous Close
$23.87
Day's Range
23.67–24.55
52-Week Range
5.26–31.97
Volume
54.21K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.55
Valuation
Market Cap
$251.86M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
2.45
EPS (ttm)Profit attributable to each share over the last twelve months.
−3.10
Financials (FY)
Revenue (FY)
$88.50M+24.08%
Net Income (FY)
−$35.27M
Profit marginThe share of revenue left as profit after all costs and taxes.
−26.97%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
10.55M
1-Year Return
+250.37%
Dividend and dates
Earnings Date
November 3, 2026
Avg Volume
100.62K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, BDSX closed at $23.93, +250.37% over 1 year.

Biodesix, Inc. (BDSX) has a market capitalization of $251.86M.

In fiscal 2025, BDSX reported revenue of $88.50M.

BDSX Stock Return by Calendar Year

Biodesix, Inc. (BDSX) return since Oct 2020: what $10,000 became

1 year
$10,000 $35,037
+250.37%
5 years
$10,000 $1,520
−84.80%
Since Oct 2020
$10,000 $934
−90.66%

If you had invested $10,000 in Biodesix, Inc. (BDSX) at the close on October 28, 2020, the earliest close on record here, it would have been worth $934 at the close on October 21, 2026: −90.66% in total, −32.73% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+251.91%
2025−77.78%
2024−16.85%
2023−20.00%
2022−56.52%
2021−73.76%
2020 (partial year)+57.38%

As of October 21, 2026.

BDSX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$88.50M−$35.27M−39.8%
2024$71.32M−$42.93M−60.2%
2023$49.09M−$52.15M−106.2%
2022$38.21M−$65.45M−171.3%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$88.50M$71.78M−$27.77M−$35.27M−39.8%
2024$71.32M$55.75M−$34.26M−$42.93M−60.2%
2023$49.09M$36.08M−$41.30M−$52.15M−106.2%
2022$38.21M$24.06M−$50.51M−$65.45M−171.3%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

BDSX Valuation vs Diagnostics & Research Median

Median of 45 stocks
MetricBDSXDiagnostics & Research medianvs median
P/S ratio2.455.2353% below
Profit margin−26.97%−0.93%26.0 pts below

Medians across 45 Diagnostics & Research stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Biodesix, Inc. (BDSX) at $251.86M. The company sits in the Healthcare sector, in the Diagnostics & Research industry. The company reports 334 employees.

The most recent close on file for BDSX is $23.93, dated October 21, 2026. That is +$0.06 (+0.25%) against the previous close. Over the past 52 weeks the price has ranged from $5.26 to $31.97. The latest close sits 354.94% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $88.50M. Against the prior fiscal year total of $71.32M, that is a change of +24.08%. The same year closed with a net loss of $35.27M. Profit margin runs at −26.97%. That is 26 percentage points below the Diagnostics & Research median of −0.93%. Trailing earnings per share are −3.1.

Across the 4 fiscal years on file, revenue moves from $38.21M in 2022 to $88.50M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 2.45 times revenue. On price-to-sales that is 53.19% below the Diagnostics & Research median of 5.23. The medians here are taken across 45 Diagnostics & Research companies that report the metric.

Beta against the wider market is reported at 0.55. Daily returns over the trailing 6 years annualize to a volatility of 100.65%. The trailing one-year total return is +250.37%. Across 5 years the annualized return works out at −31.39%.

Growth & Income

The record shows no dividend for BDSX.

The strongest complete calendar year on file is 2024 at −16.85%; the weakest is 2025 at −77.78%. Of the 5 complete calendar years on file, 0 finished higher. So far in 2026 the total return is +251.91%.

Peer Comparison

Biodesix, Inc. (BDSX) operates in the Diagnostics & Research industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Biodesix, Inc. BDSX $251.86M —
Thermo Fisher Scientific Inc. TMO $256.61B 37.4
Danaher Corporation DHR $164.40B 41.7
Natera, Inc. NTRA $59.59B —

The Diagnostics & Research industry average P/E ratio is 37.6x. Biodesix, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Diagnostics & Research Stocks

TMO

Thermo Fisher Scientific Inc.

$256.61B

 DHR

Danaher Corporation

$164.40B

 NTRA

Natera, Inc.

$59.59B

 A

Agilent Technologies, Inc.

$50.12B

 IQV

IQVIA Holdings Inc.

$45.53B

 WAT

Waters Corporation

$44.92B
View all Diagnostics & Research stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Biodesix, Inc.

Biodesix, Inc. operates as a diagnostic solutions company. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests markets as Nodify Lung Nodule Risk Assessment testing to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR, GeneStrat NGS, and VeriStrat tests markets as part of IQLung testing strategy, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to guide treatment decisions. In addition, the company provides diagnostic solutions, including translational research, initial biomarker discovery, assay design, development and validation, testing of clinical trial samples, regulatory, reimbursement, commercialization, and logistical support services for biopharmaceutical, life sciences, and diagnostic companies. Further, it operates laboratories. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.

Visit website →